Boundless Bio Inc. announced a significant corporate reorganization on May 23, 2025, involving a workforce reduction by approximately one-third as part of its portfolio prioritization strategy. The company anticipates incurring one-time costs of around $1.2 million primarily for termination benefits, including severance and healthcare. This restructuring aims to streamline operations and extend the company's cash runway into the first half of 2028, supporting anticipated clinical proof-of-concept readouts for its therapeutic programs. The company is focusing on the BBI-355/BBI-825 combination therapy and the novel Kinesin program, with plans to initiate clinical development and submit an IND application for BBI-940 by the first half of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.